Olema Pharmaceuticals Inc(OLMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 3 at 4:00 AM ET (Korea 11/3 18:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.12 | Insider Own | 19.66% | Shs Outstand | 87.5M | Perf Week | 6.8% |
| Market Cap | 0.62B | Forward P/E | - | EPS next Y | -11.21% | Insider Trans | -0.15% | Shs Float | 70.3M | Perf Month | -14.04% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -0.64 | Inst Own | 100.64% | Short Float | 22.31% | Perf Quarter | -39.88% |
| Income | -0.20B | P/S | - | EPS this Y | -28.05% | Inst Trans | 0.56% | Short Ratio | 13.28 | Perf Half Y | -51.67% |
| Sales | 0.00B | P/B | 1.44 | EPS next 5Y | -6.23% | ROA | -47.1% | Short Interest | 15.68M | Perf YTD | -71.72% |
| Book/sh | 4.92 | P/C | 1.34 | EPS past 3/5Y | 10.68% -25.06% | ROE | -52.74% | 52W High | -80.5% ($36.26) | Perf Year | -21.18% |
| Cash/sh | 5.27 | P/FCF | - | Sales past 3/5Y | - | ROIC | -47.18% | 52W Low | 13.39% ($6.24) | Perf 3Y | -55.08% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -10.16% | Gross Margin | - | Volatility(W/M) | 8.01% 6.81% | Perf 5Y | -73.65% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.86 | EPS Q/Q | -18.14% | Profit Margin | - | RSI (14) | 41.12 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.86 | Sales Q/Q | - | SMA20 | -1.48% ($7.18) | Beta | 2.13 | Target Price | $36.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/10 | SMA50 | -19.34% ($8.77) | Rel Volume | 0.95 | Prev Close | $7 |
| Employees | 131 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -10.61% - | SMA200 | -49.2% ($13.92) | Avg Volume(3M) | 1.18M | Price | $7.07 |
| IPO | 2020/11/19 | Option/Short | Yes/Yes | Trades | 7410 | Volume | 1,118,800 | Change | 1% |
🔬 Olema Pharmaceuticals trades under the ticker OLMA and is a U.S. clinical-stage biotech company focused on developing targeted therapies for breast cancer. Its lead candidate is palazestrant, an oral complete estrogen receptor antagonist and selective degrader, primarily targeting hormone receptor-positive metastatic breast cancer. The company is also developing a follow-on pipeline that targets lysine acetyltransferases.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
OLMA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -28.1% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -73.7%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.3% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #196 of 597 in the industry
Based on market cap of $619M.
NVCT#193 Nuvectis Pharma Inc $626M PER - 
AURA#194 Aura Biosciences Inc $625M PER - 
CADL#195 Candel Therapeutics Inc $621M PER - OLMA#196 Olema Pharmaceuticals Inc $619M PER - 
IAM#197 Iambic Therapeutics Inc $614M PER - 
FAQ
What kind of company is OLMA?
OLMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OLMA?
The market cap of OLMA is approximately $619M, ranking 2,965 within its sector.
What is the 52-week high and low for OLMA?
OLMA has recorded a 52-week high of $36.26 and a low of $6.24.
